1,050 Shares in United Therapeutics Corporation $UTHR Acquired by Cynosure Group LLC

Cynosure Group LLC purchased a new stake in shares of United Therapeutics Corporation (NASDAQ:UTHR) during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 1,050 shares of the biotechnology company’s stock, valued at approximately $512,000.

A number of other institutional investors and hedge funds have also bought and sold shares of the business. Clearstead Advisors LLC grew its position in United Therapeutics by 8.9% during the third quarter. Clearstead Advisors LLC now owns 280 shares of the biotechnology company’s stock valued at $117,000 after acquiring an additional 23 shares during the last quarter. Independent Advisor Alliance grew its position in United Therapeutics by 3.3% during the fourth quarter. Independent Advisor Alliance now owns 833 shares of the biotechnology company’s stock valued at $406,000 after acquiring an additional 27 shares during the last quarter. Florida Financial Advisors LLC grew its position in United Therapeutics by 5.4% during the fourth quarter. Florida Financial Advisors LLC now owns 550 shares of the biotechnology company’s stock valued at $268,000 after acquiring an additional 28 shares during the last quarter. NDVR Inc. grew its position in United Therapeutics by 5.1% during the fourth quarter. NDVR Inc. now owns 616 shares of the biotechnology company’s stock valued at $300,000 after acquiring an additional 30 shares during the last quarter. Finally, Principal Securities Inc. grew its position in United Therapeutics by 4.7% during the fourth quarter. Principal Securities Inc. now owns 686 shares of the biotechnology company’s stock valued at $334,000 after acquiring an additional 31 shares during the last quarter. 94.08% of the stock is currently owned by institutional investors.

Insider Activity

In other news, CFO James Edgemond sold 10,000 shares of the firm’s stock in a transaction that occurred on Thursday, April 2nd. The shares were sold at an average price of $561.50, for a total value of $5,615,000.00. Following the transaction, the chief financial officer owned 18,876 shares in the company, valued at approximately $10,598,874. This trade represents a 34.63% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 644,468 shares of company stock valued at $363,647,822 in the last quarter. 8.60% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on UTHR shares. Raymond James Financial started coverage on shares of United Therapeutics in a research report on Friday, April 10th. They set an “outperform” rating and a $700.00 price target on the stock. UBS Group increased their price target on shares of United Therapeutics from $655.00 to $705.00 and gave the company a “buy” rating in a research report on Thursday, March 5th. TD Cowen reiterated a “buy” rating on shares of United Therapeutics in a research report on Thursday, May 21st. Morgan Stanley set a $516.00 price target on shares of United Therapeutics in a research report on Thursday, May 7th. Finally, Wells Fargo & Company upgraded shares of United Therapeutics from an “equal weight” rating to an “overweight” rating and increased their price target for the company from $575.00 to $735.00 in a research report on Thursday, May 7th. Eleven analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $619.42.

United Therapeutics Stock Performance

Shares of United Therapeutics stock opened at $548.27 on Wednesday. United Therapeutics Corporation has a 52-week low of $272.12 and a 52-week high of $609.35. The stock has a market capitalization of $23.27 billion, a price-to-earnings ratio of 20.24, a P/E/G ratio of 1.79 and a beta of 0.57. The company’s 50 day moving average price is $566.12 and its 200-day moving average price is $522.52.

United Therapeutics (NASDAQ:UTHR) last issued its earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share (EPS) for the quarter, missing the consensus estimate of $7.00 by ($1.18). United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.The firm had revenue of $781.50 million during the quarter, compared to the consensus estimate of $797.40 million. During the same quarter in the prior year, the business posted $6.63 EPS. The firm’s revenue for the quarter was down 1.6% on a year-over-year basis. As a group, equities research analysts forecast that United Therapeutics Corporation will post 26.84 earnings per share for the current fiscal year.

United Therapeutics Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.